Premium
The ability of H 1 or H 2 receptor antagonists or their combination in counteracting the glucocorticoid‐induced alveolar bone loss in rats
Author(s) -
Ezzat Bassant A.,
Abbass Marwa M.S.
Publication year - 2014
Publication title -
journal of oral pathology and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.887
H-Index - 83
eISSN - 1600-0714
pISSN - 0904-2512
DOI - 10.1111/jop.12104
Subject(s) - endocrinology , medicine , antagonist , glucocorticoid receptor , bone mineral , receptor , glucocorticoid , dexamethasone , chemistry , osteoporosis
Background The aim of the present study was to compare between three possible osteoporotic treatments in prevention of glucocorticoid‐induced alveolar bone loss. Methods Fifty adult female Wistar rats with an average weight 150–200 g were randomized into five groups: group I (control) was intraperitoneally injected with saline. The other experimental groups ( II & III , IV & V) were intraperitoneally injected with 200 µg/100 g body weight dexamethasone. The experimental groups III , IV and V received intraperitoneal injection of 10 mg/kg/day pheniramine maleate (H1 receptor antagonist), ranitidine hydrochloride (H2 receptor antagonist) and concomitant doses of both H1 & H2 receptor antagonists respectively. After 30 days, the rats have been sacrificed. The mandibles were examined histologically, histochemically and histomorphometrically. The bone mineral density was measured using dual‐energy X‐ray absorptiometry ( DEXA ). Results Histopathologically the glucocorticoid group showed wide medullary cavities with wide osteocytic lacunae. These marrow cavities were reduced in the prophylactic groups (III, IV) but increased in group V. Bone histomorphometric analysis revealed improvement in static bone parameters in groups III and IV and deterioration in group V in comparison to group II. The DEXA revealed significant reduction in the bone mineral density in all experimental groups compared to the control group. Conclusions In a rat model, the administration of H 1 or H 2 receptor antagonists separately could minimize the alveolar bone loss caused by the administration of glucocorticoids while concomitant administration of both H 1 and H 2 receptor antagonists deteriorated the bone condition.